{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:15:17Z","timestamp":1787004917514,"version":"build-2736575974"},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"11","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background\u2003Anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibody-associated disease (MOGAD) is an immune-mediated neurological disorder with a broad spectrum of clinical presentation that is often difficult to distinguish from other demyelinating diseases, such as multiple sclerosis and neuromyelitis optica spectrum disorder.<\/jats:p>\n                  <jats:p>Objective\u2003To describe the clinical and paraclinical characteristics of MOGAD in a Brazilian tertiary center.<\/jats:p>\n                  <jats:p>Methods\u2003We retrospectively reviewed the records of adult and pediatric patients who tested positive for anti-MOG antibodies and presented with clinical and radiological diseases compatible with MOGAD.<\/jats:p>\n                  <jats:p>Results\u2003Forty-one patients (10 children) were included: 56% female, 58% Caucasian, mean age at onset 31 years (range 6-64), with a mean disease duration of 59.6 months (range 1-264 months). The most frequent onset presentation was optic neuritis (68%), acute disseminated encephalomyelitis (ADEM, 12%), and myelitis (10%). A monophasic disease course was observed in 49%. EDSS median was 2.1 at the last visit. Most patients (83%) were under continuous immunosuppressive treatment. Azathioprine was the first-line treatment in 59%. In all ADEM cases, conus, and root involvement was radiologically observed on MRI.<\/jats:p>\n                  <jats:p>Conclusion\u2003Brazilian MOGAD patients presented with a similar spectrum of previously reported MOGAD phenotypes. Conus and spinal root involvement seems to be frequently present in MOGAD-ADEM and could serve as radiologic characteristics of this clinical entity.<\/jats:p>","DOI":"10.1055\/s-0043-1777002","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T18:51:36Z","timestamp":1701370296000},"page":"980-988","source":"Crossref","is-referenced-by-count":10,"title":["Clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease in Brazil: a single-center experience"],"prefix":"10.1055","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5112-5722","authenticated-orcid":false,"given":"Katharina","family":"Messias","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Ribeir\u00e3o Preto SP, Brazil."},{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Oftalmologia, Otorrinolaringologia e Cirurgia de Cabe\u00e7a e Pesco\u00e7o, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6374-9578","authenticated-orcid":false,"given":"Renata","family":"Moreto","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Oftalmologia, Otorrinolaringologia e Cirurgia de Cabe\u00e7a e Pesco\u00e7o, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7496-5090","authenticated-orcid":false,"given":"Camila Aquino","family":"Cruz","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-1949","authenticated-orcid":false,"given":"Nathalia Rossoni","family":"Ronchi","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5502-4734","authenticated-orcid":false,"given":"Antonio Carlos dos","family":"Santos","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Imagens M\u00e9dicas, Hematologia e Oncologia Cl\u00ednica, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-9608","authenticated-orcid":false,"given":"Andr\u00e9","family":"Messias","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Oftalmologia, Otorrinolaringologia e Cirurgia de Cabe\u00e7a e Pesco\u00e7o, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2131-9438","authenticated-orcid":false,"given":"Vanessa Daccach","family":"Marques","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"M Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"885218","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management","volume":"13","author":"E Sechi","year":"2022","journal-title":"Front Neurol"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"B Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"A J Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"104442","DOI":"10.1016\/j.msard.2022.104442","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) in Chile: lessons learned from challenging cases","volume":"69","author":"J Guzm\u00e1n","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.msard.2019.02.023","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder","volume":"30","author":"S Salama","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"577987","DOI":"10.1016\/j.jneuroim.2022.577987","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: Presentation and outcomes of adults at a single center","volume":"373","author":"P Sutton","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"S Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"830488","DOI":"10.3389\/fneur.2022.830488","article-title":"Clinical Profile and Treatment Outcome in MOGAD: A Single-Center Case-Series Study in Guiyang, China","volume":"13","author":"X Lei","year":"2022","journal-title":"Front Neurol"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"M Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"21","key":"ref11","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"A Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"C L de Mol","year":"2020","journal-title":"Mult Scler"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"D K Sato","year":"2014","journal-title":"Neurology"},{"issue":"05","key":"ref14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"E P Flanagan","year":"2016","journal-title":"Ann Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.msard.2018.07.026","article-title":"Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: An ethnicity influence?","volume":"25","author":"R M Papais-Alvarenga","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"104488","DOI":"10.1016\/j.msard.2022.104488","article-title":"Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in S\u00e3o Paulo, Brazil","volume":"70","author":"G D Silva","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/jnnp-2017-317321","article-title":"Nationwide epidemiological study of neuromyelitis optica in Japan","volume":"89","author":"K Miyamoto","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2018.07.022","article-title":"Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders","volume":"26","author":"B Konuskan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","article-title":"Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients","volume":"102","author":"Y Zhao","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"37","key":"ref20","first-page":"616","article-title":"The Diagnosis and Treatment of Optic Neuritis","volume":"112","author":"H Wilhelm","year":"2015","journal-title":"Dtsch Arztebl Int"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"S Ramanathan","year":"2016","journal-title":"Autoimmun Rev"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.2147\/OPTH.S288224","article-title":"MOG-IgG- versus AQP4-IgG-Positive Optic Neuritis in Thailand: Clinical Characteristics and Long-Term Visual Outcomes Comparison","volume":"14","author":"C Narongkhananukul","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome","volume":"195","author":"J J Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.msard.2020.101965","article-title":"Prodromal headache in MOG-antibody positive optic neuritis","volume":"40","author":"S Asseyer","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"08","key":"ref25","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/acn3.51609","article-title":"SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated disorder","volume":"9","author":"M Johnsson","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1212\/WNL.98.18_supplement.1158","article-title":"A case of a 14 year old male with MOGAD (Myelin Oligocyte Glycoprotein Antibody Disease) post-COVID-19 infection responsive to high dose corticosteroids and intravenous immunoglobulin (IVIG) therapy (P9\u20131.001)","volume":"98","author":"A Balasa","year":"2022","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"577933","DOI":"10.1016\/j.jneuroim.2022.577933","article-title":"Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection: A case series","volume":"370","author":"J Lambe","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s41983-022-00496-4","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19: a case report and a review of the literature","volume":"58","author":"M A Colantonio","year":"2022","journal-title":"Egypt J Neurol Psychiat Neurosurg"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"845755","DOI":"10.3389\/fneur.2022.845755","article-title":"MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review","volume":"13","author":"Y Matsumoto","year":"2022","journal-title":"Front Neurol"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2169\/internalmedicine.0504-22","article-title":"Relapsing Anti-MOG Antibody-associated Disease Following COVID-19 Vaccination: A Rare Case Report and Review of the Literature","volume":"62","author":"H Nakano","year":"2023","journal-title":"Intern Med"},{"issue":"07","key":"ref31","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/13524585211057512","article-title":"MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination","volume":"28","author":"L Dams","year":"2022","journal-title":"Mult Scler"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1212\/NXI.0000000000000503","article-title":"MOG antibodies in combined central and peripheral demyelination syndromes","volume":"5","author":"R Vazquez Do Campo","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"01","key":"ref33","first-page":"10","article-title":"Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD","volume":"10","author":"M Nosadini","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"e2142780","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom","volume":"5","author":"C Satukijchai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands","volume":"23","author":"E D van Pelt","year":"2016","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12974-021-02160-9","article-title":"Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?","volume":"18","author":"J Havla","year":"2021","journal-title":"J Neuroinflammation"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1777002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T22:24:04Z","timestamp":1703629444000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1777002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,30]]},"published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1777002","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}